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http://dx.doi.org/10.1016/j.ccr.2014.05.020SUMMARYActivation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However,
clinical results of single-agent PI3K inhibitors have been modest to date. A combinatorial drug screen on
multiple PIK3CA mutant cancers with decreased sensitivity to PI3K inhibitors revealed that combined CDK
4/6-PI3K inhibition synergistically reduces cell viability. Laboratory studies revealed that sensitive cancers
suppress RB phosphorylation upon treatment with single-agent PI3K inhibitors but cancers with reduced
sensitivity fail to do so. Similarly, patients’ tumors that responded to the PI3K inhibitor BYL719 demonstrated
suppression of pRB, while nonresponding tumors showed sustained or increased levels of pRB. Importantly,
the combination of PI3K and CDK 4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor
regressions in PIK3CA mutant xenografts.INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K) pathway is a key regu-
lator of growth, survival, and metabolism in both normal and
malignant cells (Engelman et al., 2006; Hanker et al., 2013; Katso
et al., 2001; Miller et al., 2010; Wang et al., 2012; Yuan and Cant-
ley, 2008; Zhao and Vogt, 2008). Over 70% of breast cancers
have activation of the PI3K pathway through mechanisms such
as HER2 amplification, deletion of the tumor suppressor PTEN,
or oncogenic mutations in PIK3CA (Garcı´a-Martı´nez and Alessi,
2008). Inhibition of PI3K therefore represents a potentially attrac-
tive strategy for the treatment of breast cancer, and a number
of agents have entered clinical trials (Bachman et al., 2004;
Bendell et al., 2012; Mahadevan et al., 2012; NCT00876109;
NCT00620594; NCT01219699).
Laboratory studies and these early clinical trials indicate that
several of the PI3K inhibitors (PI3Ki) demonstrate preferential inhi-
bition of tumors with PIK3CA mutations (Bendell et al., 2012;
O’Brien et al., 2010). However, while long-term stabilization and
partial tumor responses have been observed in PIK3CA breastSignificance
Activating mutations in the PIK3CA gene, which encodes the
cancers. Thus, there have been intense efforts to develop PI3
these agents have been underwhelming to date. Our study su
responses to PI3K inhibitors and overcomes acquired resista
maintenance of pRB is a biomarker for intrinsic and acquired P
with BYL719. These findings provide rationale for study of this
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mutant cancers still do not experience substantial regressions.
We recently identified a strategy to overcome both de novo
and adaptive resistance to PI3Ki through combined inhibition
of PI3K and mammalian target of rapamycin complex (mTORC)
(Elkabets et al., 2013). Thus far, dual PI3K and mTOR inhibitors
such as BEZ235 andGDC-0980 havemade their way into clinical
trials (Markman et al., 2012), although the therapeutic window for
these agents is limited due to treatment-related toxicities. Our
present study sought to identify additional strategies that may in-
crease the efficacy of PI3Ki by both improving initial responses
and overcoming adaptive resistance.
RESULTS
PI3Ki-Resistant PIK3CA Mutant Breast Cancer Cell
Lines Fail to Undergo Growth Arrest and Maintain
Higher Levels of pS6
Despite the oncogenic activation of the PI3K pathway, PI3Ki are
not as effective as single agents as was initially hoped (Maira,catalytically active p110a subunit, occur in 30% of breast
K inhibitors to treat these cancers. However, responses to
ggests that concomitant CDK 4/6 inhibition improves initial
nce in PIK3CA mutated breast cancers. We observed that
I3K inhibitor resistance in vitro as well as in patients treated
drug combination in PIK3CA mutant breast cancer.
Figure 1. Viability, Cell-Cycle Profiles, and
Signaling in PIK3CA Mutant Breast Cancer
Cell Lineswith AcquiredResistance to PI3Ki
(A) Parental and resistant MCF7 were treated with
either the vehicle or GDC-0941 1 mM. Parental and
resistant 453 and T47D cell lines were treated with
either the vehicle or BYL719 1 mM. When vehicle-
treated cells grew to confluence, all cells were
fixed and stained for nucleic acid with Syto-60 and
absorbance was quantified. Representative plates
are shown. Data are the mean of three indepen-
dent experiments performed in triplicate. *p < 0.05
by student’s t test.
(B) Cells were treated with escalating doses of
either BYL719 or GDC-0941, as indicated, for
72 hr. Viability was assessed using Cell-Titer Glo
as described by the manufacturer. Data represent
the mean of six replicates.
(C) Cell lines were treated as indicated for 24 hr,
after which cell-cycle analysis was performed
using propidium iodide staining followed by flow
cytometry. The percentage decrease in S phase
relative to vehicle controls is depicted. Data are
the mean of three independent experiments
performed in triplicate. *p < 0.05 by student’s
t test.
(D) MCF7, 453, and T47D cells with their corre-
sponding resistant lines were treated for 24 hr with
the vehicle or the specified agent and dose, lysed,
and probed with the indicated antibodies.
All error bars in this figure represent ± SEM.
See also Figure S1 and Table S1.
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to PI3K inhibition, we studied three PIK3CA mutant breast can-
cer cell linemodels that had adapted to PI3Ki after chronic expo-
sure to the drug. Two of the cell lines, T47D and MDA-MB-453
(453), were treated with the p110a-isoform-specific inhibitor
BYL719, whereas the third cell line, MCF7, was treated with
the pan-isoform inhibitor GDC-0941.
The chronically exposed cells were more resistant to PI3Ki
than the treatment-naive (i.e., parental) cells. They demon-
strated increased viability in the presence of 1 mM PI3Ki
(BYL719 or GDC-0941, as indicated, Figure 1A) and a rightward
shift in the dose-response curve (Figure 1B). Consistent with
this finding, the chronically exposed cells exhibited less cell-
cycle arrest in response to the indicated PI3Ki, with significantly
more cells remaining in the S phase relative to parental cells
(Figure 1C). Of note, PI3Ki fail to induce substantial apoptosis
in the parental and resistant cells (Figure S1A available online).
Both parental and resistant cell lines exhibited the suppressionCancer Cell 26, 136–of Akt phosphorylation on treatment
with PI3Ki. However, phosphorylation of
S6 was maintained to a greater extent
in resistant cells, as we recently reported
(Elkabets et al., 2013) (Figure 1D).
These results suggest that sensitivity
to PI3Ki in these PIK3CA models may
be dependent on the ability to suppress
mTOR signaling and modulate cell-cycle
progression.These resistant cells also displayed cross-resistance to other
PI3Ki. For example, the T47DR and 453R cell lines were less
sensitive to GDC-0941 than the corresponding parental lines,
and the MCF7R cell line was also less sensitive to BYL719
(Figures S1B and S1C). The difference between parental and
resistant lines was less pronounced to the dual PI3K-mTORC
inhibitor BEZ235 (Figure S1D), as might be expected because
the maintenance of mTORC activity promotes resistance in
these cells. In general, the parental and resistant lines were
similarly sensitive to other targeted therapies and the chemo-
therapeutic agent paclitaxel (Figure S1E; Table S1), suggesting
that resistance is specific to inhibitors of the PI3K pathway.
Combination Drug Screen Identifies Inhibitors of
CDK 4/6, mTORC, and Akt as Sensitizers to PI3Ki
in Resistant Cell Lines
To identify potential therapeutic strategies to overcome resis-
tance to PI3Ki, we performed a combinatorial drug screen using149, July 14, 2014 ª2014 Elsevier Inc. 137
Figure 2. Combinatorial Drug Screen to Identify Sensitizers to PI3K Inhibition in Resistant PIK3CA Mutant Cell Lines
(A) An outline of the drug-screening protocol. Resistant cells were seeded in 96 well plates and treated in triplicate with escalating doses of each of the
42 compounds in the drug screen, either singly or in combination with 1 mM PI3Ki.
(B) For each of the resistant cell lines, dose-response curves to the targeted agents were generated, in the absence or presence of 1 mMBYL719 for T47DR and
453R or GDC-0941 for MCF7R. The agents were ranked according to greatest difference in AUC between these two dose-response curves for each cell line.
Targets of each agent, ranked by difference in AUC, are depicted for each cell line. Darkened values indicate statistically significant sensitizers (FDR < 0.05).
(C) Data from all three resistant cell lines were pooled and ranked by statistical significance (log(p-value)). Darkened values indicate statistically significant
sensitizers (FDR < 0.01).
See also Figure S2 and Table S2.
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and apoptosis (Figure 2A). Cell proliferation was assessed after
treatment with increasing doses of candidate drugs in the pres-138 Cancer Cell 26, 136–149, July 14, 2014 ª2014 Elsevier Inc.ence and absence of PI3Ki, and agents were ranked according
to the greatest shift in dose response that occurred with the
addition of PI3Ki. Compounds with false discovery rate (FDR)
Figure 3. The Correlation between Post-
treatment PIP3 Levels and the Capacity of
Akt Inhibition to Resensitize Resistant Cells
to PI3Ki
(A) Each resistant line was treated with escalating
doses of the agent to which it was made resistant
for 24 hr (BYL719 for 453R and T47DR, and GDC-
0941 for MCF7R). Lysates were prepared and
were probed with the indicated antibodies.
(B) Phospholipids in parental and resistant cells
were isolated after 24 hr treatment with the
vehicle or the indicated PI3Ki (for parental lines) or
continuous treatment with PI3Ki (for resistant
lines). PIP3 and PIP2 levels were measured, and
the data shown are the mean of three independent
experiments. *p < 0.05 by student’s t test.
(C) Viability was assessed in parental and resis-
tant 453 and T47D lines treated with escalating
doses of MK2206 for 5 days. Resistant lines
were also treated with escalating doses of
MK2206 in the presence of 1 mM BYL719, and
dose-response curves were generated. Viability
values for each curve were normalized to
the measured inhibition value at zero dose of
MK2206 (with and without BYL719 1 mM for
453R and T47DR). Data represent the mean of
three replicates.
(D) MCF7 and MCF7R cells were treated with
escalating doses of MK2206. MCF7R was also
treated with MK2206 in the presence of 1 mM
dose of GDC-0941 or BYL719. Viability values
for each curve were normalized to the measured
inhibition value at zero dose of MK2206 (with
and without GDC-0941 1 mM for MCF7R). Data
represent the mean of three replicates.
(E and F) Parental and resistant 453 and T47D
cells (E) and MCF7 cells (F) were treated for
24 hr with the specified agents. Lysates were
made after 24 hr and probed with the indicated
antibodies.
All error bars in this figure represent ± SEM.
See also Figure S3.
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cell line (Figure 2B; Figure S2A).
In a composite analysis of all cell lines, LEE011 emerged as the
strongest sensitizer across all three resistant models (Figure 2C).
LEE011 is a highly specific inhibitor of cyclin-dependent kinases
4 and 6 (CDK 4/6) (Figures S2B and S2C). In addition, the
allosteric mTORC inhibitor RAD001, the catalytic mTORC inhi-
bitor AZD8055, and the Akt inhibitor MK2206 were sensitizers
in two resistant lines. Five other agents sensitized just one of
the three resistant lines (Table S2). These findings suggest that
targeting downstream nodes in the PI3K signaling pathway
may sensitize PI3Ki-resistant cancers.
Akt Substrate Phosphorylation and PIP3 Levels
Correlate with Sensitization by Akt Inhibitor
The finding that Akt inhibitors overcame resistance to PI3Ki in
two of the PI3Ki resistant lines was initially surprising because
Akt phosphorylation appeared to be suppressed by PI3Ki in all
the resistant lines (Figure 1D). To determine whether certainresistant cells might retain a low level of PI3K pathway activity
in the presence of PI3Ki, we examined levels of phosphorylated
Akt (pAkt) and Akt substrates on treatment with the PI3Ki
to which each cell line was made resistant. Because both
453R and T47DR cells were resensitized to PI3Ki by an Akt
inhibitor whereas MCF7R cells were not, we compared 453R
and T47DR to MCF7R cells. On treatment with the respective
PI3Ki, we observed that phosphorylation of the Akt substrates,
ATP citrate lyase and PRAS40 (pATPCL and pPRAS, respec-
tively), were higher in 453R and T47DR than in MCF7R cells (Fig-
ure 3A). Furthermore, phosphatidylinositol (3,4,5)-triphosphate
(PIP3), which accumulates on phosphorylation of phosphatidyli-
nositol 4,5-bisphosphate (PIP2) by PI3K and therefore serves
as a more direct measure of PI3K activity, was higher in 453R
and T47DR cells relative to their parental counterparts but not
in MCF7R cells relative to MCF7 (Figure 3B). It appears, there-
fore, that residual PI3K activity may contribute to resistance to
PI3Ki in 453R and T47DR cells but not in MCF7R cells. These
results reinforce the notion that there is low-level persistenceCancer Cell 26, 136–149, July 14, 2014 ª2014 Elsevier Inc. 139
Figure 4. Combined CDK 4/6 and PI3K Inhibition in the Treatment of Resistant PIK3CA Breast Cancer Lines
(A) A dose matrix of PI3Ki, either GDC-0941 (GDC) or BYL719 (BYL) as indicated, and CDK- 4/6 inhibitor LEE011 was created in all three pairs of parental and
resistant cell lines. Viability was assessed after 5 days. Percent inhibition at each dose of the drug is presented.
(B) Cell lines were treated with vehicle (VEH) or GDC0941 (GDC) and LEE011 (LEE), in the case of MCF7R, or BYL719 (BYL) and LEE011, in the case of 453R and
T47DR, at 1 mMdoses for 24 hr. Cell-cycle analysis was then performed using propidium iodide staining followed by flow cytometry, and the percentage of cells in
sub-G1, G1, S, and G2 phases were quantified. Data are the mean of three replicates. *p < 0.05 by student’s t test.
(legend continued on next page)
Cancer Cell
CDK and PI3Ki in PIK3CA Mutant Breast Cancer
140 Cancer Cell 26, 136–149, July 14, 2014 ª2014 Elsevier Inc.
Cancer Cell
CDK and PI3Ki in PIK3CA Mutant Breast Cancerof Akt signaling in some of the resistant lines that is not appreci-
ated simply by measuring pAkt.
Consistent with this, and confirming the results of the drug
screen, the Akt inhibitor MK2206 resensitized the 453R and
T47DR cell lines to 1 mM BYL719 (Figure 3C). However,
MK2206 did not resensitize the MCF7R cells to PI3Ki (either
GDC-0941 or BYL719 1 mM) (Figure 3D). This is consistent with
the finding that PI3Ki alone was sufficient to suppress PIP3,
pAkt, and the phosphorylation of Akt substrates in the MCF7R
cells (Figures 3A and 3B). In the 453R and T47DR cells, treatment
with BYL719 partially reduced Akt substrate and S6 phospho-
rylation levels, and the addition of MK2206 enhanced suppres-
sion of these downstream nodes of the PI3K pathway (Figure 3E).
The effect appeared to be cell line, rather than inhibitor, specific
because the 453R and T47DR lines were also sensitized by
MK2206 to 1 mM GDC-0941 with similar effects on pAkt and its
substrates’ phosphorylation (Figures S3A and S3B). By contrast,
in MCF7R, the addition of MK2206 had no effect on proliferation
(Figure 3D), phosphorylation of Akt substrates (which were
largely suppressed by PI3Ki alone), or pS6 (Figure 3F), regard-
less of whether BYL719 or GDC-0941 was used as the PI3Ki.
Thus incomplete suppression of PIP3 production and sub-
sequent residual Akt signaling may contribute to resistance to
PI3Ki in some contexts and may be overcome by a combination
of PI3K and Akt inhibition.
Of note, all three resistant cell lines displayed cross-resistance
to single agent MK2206, both in regards to viability and signaling
(Figures 3C–3F). In the MCF7R cells, it appears that Akt does
not regulate mTORC1 activity. In the 453R and T47DR cells,
it is likely that elevated PIP3, pAkt, and Akt signaling at the
baseline account for the incomplete inhibition of this pathway
with Akt inhibitors alone. In T47DR (which have elevated PIP3
levels), it is also possible that PIP3 effectors other than Akt con-
tribute to sustained mTORC1 signaling. Indeed, others have
reported the importance of Akt-independent effectors of PI3K
in PIK3CA mutant breast cancers (Vasudevan et al., 2009).
We next evaluated the top sensitizer in the 453R line, lapatinib,
and confirmed that it combined with PI3Ki to further suppress
proliferation (Figure S3C) and phosphorylation of Akt substrates
and S6 (Figure S3D). This was not surprising because 453 cells
have both HER2 amplification and PIK3CA mutation, and both
contribute to the activation of PI3K signaling in these cells.
As previously discussed, the baseline absolute levels of pAkt
and PIP3 are elevated in 453R (Figures 1D and 3B) relative to
the parental cell line. Because of the higher basal levels of these
signaling molecules, treatment with a given dose of BYL719
results in higher residual levels of pAkt and PIP3 in the resistant
line than in the parental line. However, suppression of HER2
phosphorylation with lapatinib combines with BYL719 to fully(C) Parental and resistant cell lines were treated with media containing the vehicle
(L), BYL719 (B), or the indicated combinations. Fresh drugs and media were app
point all the wells were fixed and stained with Syto-60. Absorbance was measure
independent experiments performed in triplicate. *p < 0.05 by student’s t test.
(D) Twelve PIK3CA mutant (MT) and ten PIK3CA wild-type (WT) breast cance
seven concentrations for each agent and assessed for proliferation after 5 day
(see Supplemental Experimental Procedures) and ranked by synergy score.
(E) Median synergy scores between the PIK3CA mutants and wild-type lines we
All error bars in this figure represent ± SEM. See also Figure S4.inhibit this pathway (Figure S3D). These findings reinforce the
notion that residual PI3K activity contributes to the relative
resistance of certain cell lines and that the suppression of this
remaining PI3K activity reverses resistance.
CDK 4/6 Inhibition Sensitizes Cells with Acquired
and Intrinsic Resistance to PI3K Inhibition
In the present study, the highest-scoring drug in the composite
analysis of the drug screen was LEE011, a highly specific CDK
4/6 inhibitor currently under clinical development (Figures S2B
and S2C). To confirm that the combination of CDK 4/6 and
PI3Ki exhibit synergistic activity against PIK3CA mutant breast
cancer cell lines, we treated each of the parental and resistant
cell lines with increasing concentrations of PI3Ki and LEE011
alone and in combination. As observed previously, PI3K inhibi-
tion alone was relatively ineffective at inhibiting the proliferation
of resistant cells (Figure 4A). However, for all three resistant
cell lines and, to a lesser extent, parental lines, we observed a
synergistic interaction between LEE011 and PI3Ki in suppress-
ing cell proliferation (Figure 4A; Figure S4A). The combination
effect in the resistant lines appeared to rely on cell-cycle arrest
rather than apoptosis because an increase in the population
of cells in G1, but not sub-G1, was observed (Figure 4B). Cell-
cycle arrest ultimately translated into decreased long-term cell
viability (Figure 4C).
The chemically unrelated CDK 4/6 inhibitor PD-0332991 also
sensitized the resistant lines to PI3K inhibition (Figures S4B
and S4C), indicating that the observed effects of LEE011 are
probably on target. Similar results were obtained using siRNA
to CCND1 (which encodes for Cyclin D1) or CDK4 and CDK6
(Figure S4D).
The initial screen was performed in PIK3CA mutant breast
cancer cells that had developed resistance after chronic expo-
sure to PI3Ki. However, we also aimed to determine whether
this combination is effective in PIK3CA mutant cancers that
were intrinsically resistant to single-agent PI3Ki. Importantly,
adding LEE011 increased the efficacy of PI3Ki in five different
PI3KCA mutant breast cancer cell lines with intrinsic resistance
to PI3Ki (Figure S4E). In all but one line (MFM223), the effect of
the combination was greater than the single agents alone.
The BYL719-LEE011 combination was examined more
broadly in a panel of 22 breast cancer cell lines (Figures 4D
and 4E). This panel included 12 PIK3CA mutant and 10 PIK3CA
wild-type lines (Barretina et al., 2012). Combination effects
were scored relative to Loewe dose-additivity (see Supplemental
Experimental Procedures) using a weighted synergy score
calculation (Leha´r et al., 2009). A comparison of the combination
effects between the two subsets of cell lines demonstrated
stronger synergy (p = 0.012, ANOVA) in the PIK3CA mutants,(V) or the following drugs, as indicated at 1 mM doses: GDC-0941 (G), LEE011
lied every 72 hr until the vehicle-control-treated wells were confluent, at which
d using an infrared imager and quantified. Data depicted are the mean of three
r cell lines were treated with BYL719 and LEE011 in dose matrices across
s. The response of each cell line to the combination was scored for synergy
re compared. *p < 0.05 by ANOVA.
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Figure 5. Comparison of RB Phosphorylation between Resistant Lines and Sensitive Lines following PI3K Inhibition, PI3K-mTORC Inhibition,
and PI3K-CDK Inhibition
(A) Parental and resistant cells were seeded and treated with either AZD-8055 (8055) 500 nM or the indicated PI3Ki 1 mM, either alone or in combination. Lysates
were made after 24 hr of treatment and probed with the indicated antibodies.
(legend continued on next page)
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larly susceptible to this combination.
RB Phosphorylation Is Maintained in the Setting
of PI3Ki Resistance but Suppressed by Either
mTORC or CDK 4/6 Inhibitors
Recently, it was reported that the suppression of TORC1 sig-
naling is necessary for sensitivity of PIK3CA mutant cancers to
PI3Ki, and that combined PI3K and TORC1 inhibition is effective
in PIK3CA mutant cancers in which PI3Ki do not fully inhibit
TORC1 (Elkabets et al., 2013). Consistent with this finding, the
combination of TORC1 plus PI3K inhibition scored high in our
drug screen. However, it was not known whether specific
TORC1 outputs exist whose inhibition is critical for response to
PI3Ki. That CDK 4/6 emerged as the strongest sensitizer to
PI3Ki was therefore particularly interesting to us given that
CDK 4/6 exerts its activity by binding and activating Cyclin D1,
whose expression is often regulated by TORC1 (Averous et al.,
2008; Takuwa et al., 1999). The CDK 4/6-Cyclin D1 complex
phosphorylates and inactivates the tumor suppressor RB and
other pocket proteins. In turn, RB, when phosphorylated, re-
leases E2F transcription factors, thereby promoting cell-cycle
progression from G1 to S phase. We therefore questioned
whether RB remains phosphorylated, i.e., inactive, in the setting
of resistance to PI3Ki andwhether sensitization to PI3K inhibition
by CDK 4/6 inhibitors occurred via dephosphorylation, i.e., acti-
vation, of RB.
Consistent with this hypothesis, we noted that, although PI3Ki
monotherapy led to the suppression of pAkt and phosphorylated
RB (pRB) in treatment-naive, sensitive PIK3CA mutant breast
cancer cell lines, it was insufficient to suppress pRB or mTORC1
substrates in the resistant lines (Figure 5A). The addition of
mTORC inhibition, however, led to downregulation of Cyclin D1
and suppression of pRB in these resistant lines (Figures 5A
and 5B). Thus, maintenance of RB phosphorylation in the resis-
tant lines was due to a failure to suppress mTORC signaling.
We also observed that CDK 4/6 inhibition suppressed pRB in
the lines with acquired resistance (Figures 5C and 5D) and that
siRNA directed against CCND1 or CDK4 and CDK6 yielded the
same effect (Figure S4D). Thus, in the resistant cells, it appeared
that PI3K inhibition suppressed Akt phosphorylation but failed to
suppress CDK 4/6 activity, as measured by RB phosphorylation.
By adding either an mTORC or CDK 4/6 inhibitor to a PI3Ki in
the resistant cells, RB phosphorylation was suppressed, as
well as Akt, recapitulating the effect of single-agent PI3Ki in the
sensitive cells. RB knockdown in parental MCF7 and 453 cell
lines conferred resistance to LEE011 (Figure S5A); moreover,
RB knockdown in resistant lines led to resistance to the com-
bination of LEE011 and PI3Ki (Figure S5B), further supporting
that the effects of CDK 4/6 inhibition on these cells aremediated,
at least in part, via RB activation.
Investigations were undertaken to determine whether the
restoration of RB function was necessary for the growth arrest
induced by PI3Ki in sensitive cells. CCND1 overexpression(B) Cells were prepared and treated as in (A) but lysed with buffer containing 0.1
(C) Cells were treated with PI3Ki 1 mM or LEE011 1 mM, alone or in combination,
(D) Cells were prepared and treated as in (C) but lysed with buffer containing 0.1
See also Figure S5.limited the suppression of pRB by PI3K inhibition but only
partially abrogated the response to PI3Ki (Figures S5C and
S5D). Perhaps this should not be surprising because PI3K inhibi-
tion still suppressed growth signals such as Akt and mTORC1
(Figure S5D). Similarly, knockdown of RB was insufficient to
cause resistance to PI3Ki (Figures S5E and S5F). However, in
addition, in the setting of RB-knockdown experiments, the
increased expression of other pocket proteins (such as p107)
may have compensated for RB loss in cells treated with PI3Ki
(Figure S5F). Indeed, a subset of E2F target genes was still
suppressed by PI3K inhibition in the RB-knockdown cells (Fig-
ure S5G). Furthermore, both mTORC1 and Akt were still sup-
pressed in by PI3Ki in the RB-knockdown cells (Figure S5F).
In total, these experiments suggest that inhibition of Cyclin
D-CDK 4/6 activity is not the sole mediator of growth arrest in
response to PI3Ki, at least when Akt and mTORC1 are still sup-
pressed. However, when combined with PI3Ki in a resistant line,
both Akt and Cyclin D-CDK 4/6 are inhibited, leading to the
impairment of cell-cycle progression (Figure 4B).
Maintenance of pRB May Serve as a Clinical Biomarker
of Both Acquired and De Novo Resistance to
Single-Agent PI3K Inhibition
The findings noted here suggest that the suppression of pRB
may serve as a biomarker for response to PI3K inhibition. Indeed,
a good correlation exists between the doses of PI3Ki required to
inhibit cell proliferation and RB phosphorylation in sensitive
parental lines (Figure S6A; Figure 1B), and resistant cells failed
to suppress RB phosphorylation in response to PI3Ki. Thus,
we determined whether suppression of RB phosphorylation
among treatment-naive PIK3CA mutant breast cancers corre-
latedwith sensitivity to single-agent PI3Ki. As shown in Figure 6A,
in a panel of 10 PIK3CA mutant breast cancer cell lines, the
suppression of pRB correlated with sensitivity to BYL719. The
effect appeared to be unrelated to the PI3Ki that was used; in
the intrinsically resistant CAL51 cells, the addition of either
BYL719 or GDC-0941 led to a reduction of pAkt but did not
suppress pRB unless LEE011 was added (Figure S6B).
To determine whether the analysis of changes in pRB would
similarly discriminate sensitive from resistant cancers in patients,
we assessed eight paired biopsy specimens of patients enrolled
in clinical trials of BYL719. Patients were classified as re-
sponders or nonresponders, as previously described (Elkabets
et al., 2013). Patients with a response to PI3Ki had initial
suppression of pRB on treatment relative to the baseline; non-
responders had maintained or increased levels of pRB on
treatment relative to the baseline (Figures 6B–6D; Figure S6C).
Moreover, three patients who initially responded ultimately pro-
gressed and had biopsies at that time. Although the responding
cancer had suppression of pRB, when it became resistant, pRB
levels were restored. These data demonstrate that suppression
of pRB may be a marker of response to PI3Ki therapy in the
clinic and reinforce the notion that combined treatment with a
CDK 4/6 inhibitor may have increased clinical antitumor activity.% SDS.
and cell lysates were prepared and probed as in (A).
% SDS.
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Figure 6. Correlation between Posttreatment pRB Levels and Sensitivity to Single-Agent PI3Ki In Vitro and in Patient Biopsy Specimens
(A) Five sensitive PIK3CAmutant cell lines (IC50% 400nM to BYL719) and five de novo resistant PIK3CA cell lines (half-maximal inhibitory concentration (IC50)R
800 nM to BYL719) were treated with media or with BYL719 1 mM (BYL) for 24 hr, and lysates were probed with the indicated antibodies. The fraction of remaining
pRB (relative to actin) was calculated for both the sensitive and resistant lines, and a student’s t test was performed. *p < 0.05 by student’s t test.
(B) Eight patients enrolled in early clinical trials of BYL719 were classified as responders or nonresponders, as previously described (Elkabets et al., 2013) (n = 4 in
each group). Biopsy specimenswere collectedwithin 2 weeks prior to the start of treatment andwhile on treatment. Slides were prepared, stained, and scored for
pRB (see Supplemental Experimental Procedures). The percentage change relative to pretreatment levels of pRB for both the responders and the nonresponders
is depicted. *p < 0.05 by student’s t test.
(C) Representative sections from a tumor that initially responded to BYL719, with immunohistochemical (IHC) staining for pRB 780 in paired biopsies prior to
treatment, on day 56 of BYL719 (during response), and at progression, with quantitative H-score.
(D) Representative sections from a nonresponsive tumor to BYL719, with IHC staining for pRB 780 in paired biopsies prior to treatment and at day 56 of BYL719,
with quantitative H-score.
All error bars in this figure represent ± SEM. See also Figure S6.
Cancer Cell
CDK and PI3Ki in PIK3CA Mutant Breast CancerCombining PI3Ki and LEE011 Overcomes Intrinsic
and Acquired Resistance In Vivo
The efficacy of this combination was next examined in vivo. The
activity of this combination was initially examined in vivo using
tumor xenografts derived from theMCF7R line, andwe observed144 Cancer Cell 26, 136–149, July 14, 2014 ª2014 Elsevier Inc.a nonsignificant trend toward improved efficacy of the combina-
tion over either single-agent therapy (Figure S7A). Although this
activity confirmed our in vitro studies, we turned our attention
to studying treatment-naive PIK3CA mutant breast cancer
models. Despite the sensitivity of some PIK3CA mutant breast
Figure 7. PI3K-CDK 4/6 Inhibitor Combina-
tion in PIK3CAMutant Breast Cancer Xeno-
grafts In Vivo
(A) MCF7 xenografts were treated with LEE011
(LEE) 75mg/kg/day, GDC-0941 (GDC) 100mg/kg/
day, or the combination of the two. At day 28, three
MCF7 xenografts that had progressed on GDC-
0941 monotherapy had LEE011 75 mg/kg/day
added to their regimen. *p < 0.05 by one-way
ANOVA Kruskal-Wallis test, with Dunn’s multiple
group comparison test.
(B) MCF7 xenografts were treated with the indi-
cated drugs for 72 hr, at which point tumors were
harvested and snap frozen. Lysates were pre-
pared and probed with the indicated antibodies.
(C) CAL51xenograftswere treatedwith the vehicle,
GDC-0941 100mg/kg/day, LEE011 75mg/kg/day,
or the combination of GDC and LEE. *p < 0.05 by
one-way ANOVA Kruskal-Wallis test, with Dunn’s
multiple group comparison test.
(D) CAL51 xenografts were treated with the indi-
cated drugs for 72 hr, at which point tumors were
harvested and snap frozen. Lysates were pre-
pared and probed with the indicated antibodies.
(E) T47D xenografts were treated with the vehicle,
BYL719 25 mg/kg/day, LEE011 75 mg/kg/day, or
the combination of BYL and LEE. *p < 0.05 by
one-way ANOVA Kruskal-Wallis test, with Dunn’s
multiple group comparison test.
(F) T47D xenografts were treated with the indi-
cated drugs for 72 hr, at which point tumors were
harvested and snap frozen. Lysates were pre-
pared and probed with the indicated antibodies.
(G) 453 xenografts were treated with the vehicle,
BYL719 10 mg/kg/day, LEE011 75 mg/kg/day, or
the combination of BYL and LEE. *p < 0.05 by
one-way ANOVA Kruskal-Wallis test, with Dunn’s
multiple group comparison test.
Tumor measurements in this figure were per-
formed as described in the Supplemental Experi-
mental Procedures. All error bars in this figure
represent ± SEM. See also Figure S7.
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single-agent activity of PI3Ki in vivo, even in the most sensitive
models in vitro, is modest (Elkabets et al., 2013; Jamieson
et al., 2011; Liu et al., 2013; Ma et al., 2014; Wong et al., 2013;
Yuan et al., 2011). This is highly consistent with the clinical trial
results to date, in which there has been limited clinical activity
of PI3Ki as single agents in PIK3CA mutant breast cancers.
Thus, we speculated that the PIK3CA mutant cancers that
were sensitive in vitro take on more resistant features in vivo,
perhaps maintaining CDK 4/6 activity.
We first examined the MCF7 xenograft tumor models and
noted that single-agent GDC-0941 slowed tumor growth but
failed to induce regressions (Figure 7A). Although Akt suppres-
sion by GDC-0941 was noted, RB phosphorylation was unaf-
fected (Figure 7B). Although the reason for the relative discor-
dance between in vivo and in vitro sensitivities remains unclear,
importantly, the correlation with resistance and maintenance of
RB phosphorylation was retained in vivo and was effectively
overcome by the addition of a CDK 4/6 inhibitor. We also exam-
ined the efficacy of the combination of LEE011 and GDC-0941
in the xenograft model of the CAL51 cells, a PIK3CA mutantbreast cancer line that had maintained RB phosphorylation and
was resistant in vitro (Figure S4E). Single-agent GDC-0941
slowed CAL51 tumor growth, but progression still occurred (Fig-
ure 7C). Pharmacodynamic studies demonstrated that single-
agentGDC-0941partially suppressed pAkt but failed to suppress
RB phosphorylation (Figure 7D). However, the combination with
LEE011 led to the concomitant suppression of RB phosphory-
lation and suppression of tumor growth (Figures 7C and 7D).
In T47D xenografts, we also observed a significantly improved
effect from combination therapy compared to either single-agent
BYL719 or single-agent LEE011 (Figure 7E). Similar to the MCF7
xenograft tumors, single-agent PI3Ki led only to tumor stasis
and failed to potently suppress RB phosphorylation, despite
the suppression of pAkt (Figure 7F). However, mice treated
with the combination experienced suppression of both pAkt
and pRB (Figure 7F). We also treated 453 xenografts with
BYL719 and LEE011, alone and in combination. In this model,
regressions were noted with single-agent LEE011 therapy, but
the combination of agents BYL719 and LEE011 led to complete
regressions (Figure 7G). Furthermore, tumors were measured
after cessation of treatment on day 21, and whereas theCancer Cell 26, 136–149, July 14, 2014 ª2014 Elsevier Inc. 145
Figure 8. Inhibition at Vertical Nodes in the
PI3K Pathway Improves Efficacy of PI3Ki
Combined inhibition of PI3K and Akt (indicated by
the dashed bracket) is synergistic only in resistant
models that maintain PIP3 and phosphorylation
of Akt substrates (453R, T47DR). Combined inhi-
bition of PI3K and mTOR or PI3K and CDK 4/6
(indicated by the solid brackets) is synergistic in all
resistant models, including those that maintain
PIP3 and phosphorylation of Akt substrates (453R,
T47DR) and those that do not (MCF7R). *Some
resistant models maintain low-level flux through
the PI3K and Akt pathways.
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CDK and PI3Ki in PIK3CA Mutant Breast CancerLEE011 monotherapy cohort experienced tumor growth roughly
2 weeks later, mice treated with the combination of agents had
not exhibited tumor recurrence at the completion of the study,
5 weeks following treatment cessation.
Although our primary objective was to determine whether
combined CDK 4/6 and PI3Ki would be a useful strategy as the
first-line PI3Ki-based therapy, we did also examine the efficacy
of adding LEE011 after the clear development of resistance to
single-agent GDC-0941 in the MCF7 xenografts. Three of the
MCF7 xenografts with tumor growth onGDC-0941monotherapy
had LEE011 75 mg/kg added at day 28 and experienced regres-
sions over the subsequent 3 weeks (Figure 7A).
Thus, the combination of PI3Ki, pan or p110a-specific, with
LEE011 was highly effective in four different models of PIK3CA
mutant breast cancer with good tolerability as determined by
the stability of animal weight on treatment (Figures S7B and
S7C). These data together suggest that the combination of
PI3K and CDK 4/6 inhibitors have substantial antitumor activity
in PIK3CA mutant breast cancers.
DISCUSSION
PI3Ki have led to tumor stabilization and some disease re-
sponses in PIK3CA mutant breast cancer. However, dramatic
tumor regressions are not typical. Multiple recent reports have
described mechanisms of resistance to PI3Ki, including MYC
overexpression and amplification (Ilic et al., 2011; Liu et al.,
2011), matrix-associated resistance (Muranen et al., 2012),
activity of RSK 3/4 (Serra et al., 2013), and mTORC activation
(Elkabets et al., 2013). The goal of the present study was to
identify ways to improve the efficacy of PI3Ki-based therapy
by overcoming adaptive resistance but, importantly, also by
improving initial responses to PI3Ki-based treatment.
By studying experimentally generated PI3Ki-resistant cell-line
models, we identified two distinct models of resistance to PI3K
inhibition (Figure 8). In the first model (453R and T47DR), residual146 Cancer Cell 26, 136–149, July 14, 2014 ª2014 Elsevier Inc.Akt signaling allows for sustained activity
of mTORC and its downstream effectors.
Fully suppressing Akt signaling with an
Akt inhibitor suppressed the phosphory-
lation of downstream nodes such as
PRAS40 and mTORC and synergized
with PI3K inhibition. In the second model
of resistance (MCF7R), PI3K remainspotently inhibited, as evidenced by suppressed PIP3 levels and
Akt substrates, but mTORC activity is sustained, probably
through input from other pathways. In this model, as expected,
there is no added benefit from Akt inhibition in combination
with PI3K inhibition. Importantly, targeting downstream at CDK
4/6 sensitized both types of resistance models to PI3Ki, high-
lighting the potential clinical utility of this combination across
cancers that fail to respond to PI3Ki due to diverse mechanisms.
The CDK 4/6 pathway has been implicated in a broad spec-
trum of cancers, including breast cancer, colon cancer, prostate
cancer, and hematologic malignancies (Arima et al., 2008; Choi
et al., 2012; Gazzeri et al., 1998; Gouyer et al., 1998; Grewe
et al., 1999; Myklebust et al., 2012; Nakamura et al., 2013; Niel-
sen et al., 1998; Petrovic et al., 2013). Notably, targeting this
pathway has already been shown to have efficacy in breast
cancer (NCT00721409). In a phase 2 trial in patients with
hormone-receptor-positive disease, the addition of the CDK
4/6 inhibitor PD-0332991 to letrozole as frontline therapy caused
a statistically significant improvement in progression-free sur-
vival from 7.5 to 26.2 months. The data provided in this article
point to the potential potency of using these agents in combina-
tion with PI3Ki in PIK3CA mutant cancers.
This study reveals that insensitivity to PI3Ki is evident by
persistent RB phosphorylation and can be effectively overcome
by combining a CDK inhibitor with a PI3Ki. In vitro, we noted that
PIK3CA breast cancer cell lines with both de novo and acquired
resistance maintained RB phosphorylation with PI3Ki treatment.
Moreover, in samples from patients treated with BYL719, there
was a tight correlation between patient response to BYL719
and the suppression of pRB, supporting the notion that failure
to suppress RB phosphorylation is associated with resistance
to PI3Ki. In studies of xenograft tumor models in vivo, PI3Ki led
to slower growth but not frank regression, mimicking responses
typically observed in the clinical setting with PI3K monotherapy.
It is notable that this includes cell lines (e.g., MCF7 and T47D
cells) whose proliferation was strongly inhibited in vitro.
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agent PI3Ki in these models. It may be that the maintenance
of RB phosphorylation contributed to the reduced efficacy of
PI3Ki in vivo. Although the reason for the differences between
in vitro and in vivo sensitivity is not immediately apparent, impor-
tantly, persistent RB phosphorylation continued to correlate well
with resistance in vivo and in patient samples. Because the
addition of a CDK 4/6 inhibitor led to the loss of pRB and to
tumor regressions in the in vivo models, we are optimistic that
a similar benefit will be observed in patients.
Althoughmaintenance of pRBwas associatedwith resistance,
we observed that loss of RB alone was not sufficient to cause
resistance to PI3K inhibition. There may be two reasons for this
observation. First, there may be contributions from other pocket
proteins with overlapping functions to RB, which may com-
pensate for RB loss. This phenomenon has been observed, for
example, inRb/mouse fibroblasts in which there is a compen-
satory increase in p107 protein levels (Sage et al., 2003). Indeed,
we observed that p107 expression was higher in RB-knockdown
cells relative to control cells on treatment with PI3Ki. Second, the
loss of RB alone may be insufficient to cause resistance in cells
where PI3K inhibition continues to potently suppress multiple
other effectors, such as Akt and mTORC.
Previous laboratory studies have demonstrated that PIK3CA
mutant breast cancers are among the most sensitive to single-
agent PI3Ki (Beaver et al., 2013; O’Brien et al., 2010), and several
clinical development plans for PI3Ki exist in this genetically
defined subset of breast cancer. Although not all PIK3CAmutant
cell lines that we examined exhibited synergy with the combi-
nation, it is also notable that the PI3K-CDK 4/6 inhibitor combi-
nation is generally more synergistic in PIK3CA mutant breast
cancers than the wild-type counterparts. For these reasons,
we favor the initial clinical development of this combination
in breast cancers harboring PIK3CA mutant breast cancers.
However, the studies herein do not fully demonstrate that this
combination will be ineffective in other subsets of breast cancer.
Although we have previously reported an effective strategy to
overcome resistance to PI3Ki, namely combined mTORC-PI3K
inhibition (Elkabets et al., 2013), CDK 4/6-PI3K inhibition is an
alternative therapeutic strategy for PIK3CA mutant breast can-
cer. Given that the most common side effects of PI3K inhibition
are hyperglycemia, rash, and gastrointestinal toxicity and those
of CDK 4/6 inhibition are primarily hematologic, we are encour-
aged that the nonoverlapping toxicity profile between the two
agents may be well tolerated in patients, as they were in the
in vivo studies. Indeed, it is likely that therapeutic index in the
clinical setting will strongly impact which combination strategy
will be more useful for treating PIK3CA mutant breast cancer.
In summary, our findings suggest that resistance to PI3K inhi-
bition can be reversed by the activation of RB using CDK 4/6
inhibition, and further study of this combination in the clinical
setting is warranted.EXPERIMENTAL PROCEDURES
Cell Lines
Cell lines were verified by SNP or short tandem repeat (STR) analysis and
maintained at 37C in a 5% CO2 incubator. To generate resistant lines, the
parental cell lines were treated with increasing concentrations of the kinaseinhibitor (starting at the 10% growth inhibitory concentration, GI10), until a
target concentration of 1 mM of PI3Ki was achieved.
Western Blotting
Unless otherwise indicated, resistant cells were removed from the drug in
which they were cultured for 72 hr prior to experiments. Cells were plated
and treated the following day with the indicated agent for 24 hr, after which
the cells lysed. Proteins were resolved using the NuPAGE Novex Midi Gel sys-
tem (Invitrogen).
Flow Cytometry
Cells were plated and treated the following day with the indicated agents. For
cell-cycle analyses, treatments were for 24 hr, after which the cells were
washed, permeabilized with triton, treated with RNase A, and stained with
propidium iodide. Fluorescence-activated cell-sorting (FACS) analysis was
performed on an LSR II flow cytometer (BD Biosciences).
Viability Studies
Long-term viability assays were performed by plating and treating the
following day with the indicated agent, with drug and media replenished every
3 days until the vehicle-treated cells reached confluence (8–12 days). Cells
were fixed and stained with Syto60 nucleic acid stain.
Combinatorial Drug Screen
Resistant lines were plated in 96 well plates and treated with escalating doses
of each of the 42 agents in the drug screen, in the absence or presence of
PI3Ki. Drugs were used at doses that reflected their single-agent activity in a
broad spectrum of cancer cell lines (Novartis internal data). At the end of
5 days, proliferation was assessed using Cell Titer Glo. Growth inhibition
values were normalized to the measured inhibition value at zero dose of the in-
dex compound, with or without PI3Ki. Differences in area under the curve
(AUC) with and without PI3Ki for each compound were calculated.
Patients
Patients were enrolled in the phase 1 clinical study of BYL719 (NCT01219699)
and the response was assessed per RECIST (response evaluation criteria
in solid tumors) criteria. Staging scans were performed prior to treatment
and every two cycles. Biopsies were obtained within 2 weeks of starting
the study agent, at the end of cycle 2, and at progression. Response was
defined as previously described (Elkabets et al., 2013). On treatment and pro-
gression, specimens were collected between 4 and 6 hr of the last treatment
dose. All human studies were approved by the Massachusetts General
Hospital Institutional Review Board, and informed consent to study was
obtained as per protocol from all patients. Please see Supplemental Experi-
mental Procedures for discussion of immunohistochemistry procedures.
Mouse Xenograft Studies
Female nude mice were used for MCF7, T47D, and CAL51 xenograft models,
and SCID mice were used for MD-AMB-453 xenografts. For MCF7 and T47D
xenografts, estrogen-pellet implantation was performed. Tumors were moni-
tored until they reached an average size of 300 mm3, roughly 2–3 weeks, at
which point treatments were begun. All mice were euthanized using CO2
inhalation per institutional guidelines at Massachusetts General Hospital or
Novartis Institute for Biomedical. Experiments were approved by the Institu-
tional Animal Care and Use Committee at Massachusetts General Hospital
or Novartis Institute for Biomedical Research.
Statistical Analyses
Unless otherwise specified, student’s t tests were performed for statistical
analysesandpvalues<0.05wereconsideredsignificant.Statistical comparison
among groups in xenograft studies was carried out with one-way ANOVA Krus-
kal-Wallis test, with Dunn’s multiple group comparison test (GraphPad Prism).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
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